Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
Authors
Keywords
-
Journal
Targeted Oncology
Volume 13, Issue 2, Pages 205-216
Publisher
Springer Nature
Online
2018-03-01
DOI
10.1007/s11523-018-0559-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reply to B. Rini et al and S. Buti et al
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
- (2017) Naveen S. Basappa et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC.
- (2017) Yoshihiko Tomita et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis
- (2016) Benoît Rousseau et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2016) Jose Manuel Ruiz-Morales et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of therapeutic effects and the risks of hypertension and hyperglycemia in patients with renal cell carcinoma who were receiving antiangiogenic drugs
- (2016) Lingling Chang et al. Journal of Cancer Research and Therapeutics
- 2617 A Prospective Randomized Phase-II Trial with Temsirolimus vs. Sunitinib in non-clear Renal Cell Carcinoma. A Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and Interdisciplinary Renal Cell Carcinoma Group of the German Cancer Society (IAGN)
- (2015) L. Bergmann et al. EUROPEAN JOURNAL OF CANCER
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
- (2015) Ariana Znaor et al. EUROPEAN UROLOGY
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- (2015) Borje Ljungberg et al. EUROPEAN UROLOGY
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
- (2015) Jenny J Ko et al. LANCET ONCOLOGY
- First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
- (2014) J J Ko et al. BRITISH JOURNAL OF CANCER
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
- (2014) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network meta-analysis, electrical networks and graph theory
- (2012) Gerta Rücker Research Synthesis Methods
- Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma
- (2011) Shiro Hinotsu et al. International Journal of Clinical Oncology
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Contemporary Epidemiology of Renal Cell Cancer
- (2010) Wong-Ho Chow et al. CANCER JOURNAL
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
- (2009) S. Negrier et al. MEDICAL ONCOLOGY
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation